



Congenital toxoplasmosis can cause miscarriage and neurological and/or eye damage 
to the fetus. Since Austria and France established the prenatal screening, the prevalence 
of toxoplasmosis has declined from 50% to 35% and 84% to 44%, respectively. Other 
countries, such as the United Kingdom, have educational practices to reduce the risk of 
infection in seronegative pregnant women. In Brazil, prenatal screening is carried out in 
the states of Mato Grosso do Sul and Minas Gerais and the cities of Curitiba and Porto 
Alegre. In Londrina, state of Parana, the “Health Surveillance Program for Toxoplasmo-
sis Acquired during Pregnancy and Congenital Toxoplasmosis” was established, which is 
based on serological screening, advising on prevention measures and quarterly serologi-
cal monitoring in pregnant women that are initially seronegative, in addition to the mon-
itoring of pregnant women and children with acute infection and case notification. In the 
first four years of implementation, the program evaluation showed a 63% reduction in 
the number of pregnant women and 42% in the number of children referred to reference 
services, resulting in the opening of vacancies for the care of patients with other diseases. 
As for medications, there was a 62% reduction in consumption of folic acid and 67% of 
sulfadiazine. Moreover, the definition of the protocols resulted in the standardization 
of care and safety for the decision-making by physicians. Therefore, as there are several 
protocols individualized in various departments and regions, the establishment of an 
ideal, consensual conduct with technical support, will result in implementing measures 
that will certainly save public resources, with the decrease in congenital toxoplasmosis.
Keywords: Toxoplasmosis, congenital; pregnant women; health programs and plans; 
primary prevention; secondary prevention; tertiary prevention.
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INTRODUCTION
Congenital toxoplasmosis has a major socioeconomic 
impact, especially if the child is affected by mental re-
tardation and blindness1. The prenatal screening is car-
ried out in some European countries, such as France, 
Austria, Slovenia, Germany, Switzerland, Italy and Bel-
gium, and is based on the detection of IgG and IgM an-
tibodies of the mother2.
The analysis of cost and effectiveness of screening 
programs is important in public health policy decisions. 
Lappalainen et al.3 performed a cost-benefit study in 
Finland, where the prevalence in pregnant women is 
20.3% and the incidence of congenital toxoplasmosis 
is 2.4 per 1,000 and concluded that the prenatal screen-
ing associated with health education is economically vi-
able when the incidence of maternal infection exceeds 
1.1 per 1,000 pregnant women; however, the authors 
recommend screening even in countries with low inci-
dence of the disease, due to the serious consequences of 
congenital toxoplasmosis. Countries with a congenital 
toxoplasmosis prevention program have low prevalence 
of the disease, confirming the importance of preventing 
infection in pregnant women4. 
Congenital toxoplasmosis and its sequelae can be 
avoided through primary prevention (information to 
susceptible pregnant women about the sources of in-
fection), by serological prenatal screening (gestational 
toxoplasmosis identified as early as possible, followed 
by antibiotic treatment to prevent or limit the transpla-
cental transmission and fetal diagnosis and treatment) 
and also by neonatal screening, followed by antimicro-
bial treatment of infected newborns to prevent clinical 
damage5. 
The primary prevention programs should be based 
on epidemiological and cultural characteristics of each 
region. Thus, determining risk factors in each popula-
tion is of vital importance to determine health promo-
tion strategies that should be based on the knowledge 
of factors that affect the behavior of pregnant women6. 
Suggestions made by the healthcare professionals to 
at-risk pregnant women are more effective than print-
ed recommendations (magazines, brochures, posters), 
which are insufficient to change risk behaviors for toxo-
plasmosis7,8. Thus, it is essential that healthcare profes-
sionals be trained on prevention measures, in order to 
appropriately advise pregnant women9. Countries with 
high prevalence of toxoplasmosis successfully instituted 
secondary prevention programs through maternal se-
rum screening10. 
The cost-benefit of prenatal screening is considered 
acceptable amidst the definition of the high preva-
lence in the population (above 40% of seroprevalence 
in women of childbearing age), whereas in areas of low 
prevalence, a screening test can be used11.
Toxoplasmosis prevention strategies, adopted by the 
several public health systems, are not uniform across 
different countries or even inside a country. Countries 
with high incidence of infection, such as France12, Aus-
tria13 and Slovenia4, implemented prenatal screening 
programs, whereas countries with low incidence of the 
disease have adopted neonatal screening, such as Den-
mark14 and Poland15. The US16 and the UK17, where toxo-
plasmosis is rare, have no universal serologic screening 
program. 
PROGRAMS FOR CONTROL OF CONGENITAL TOXOPLASMOSIS 
IN THE WORLD
MATERNAL SCREENING PROGRAMS
The maternal serum screening for detection of toxoplas-
mosis is an important tool, which allows the adoption of 
early prophylactic and therapeutic measures, thus reduc-
ing the rate of vertical transmission and/or fetal develop-
ment impairment18. Therefore, it is essential to start the 
prenatal care in the first trimester of pregnancy, perform-
ing the serological screening, allowing the early identi-
fication of acute cases of gestational toxoplasmosis19. In 
cases of seronegativity, the test should be repeated in the 
second and third trimesters of pregnancy4. 
According to Mitsuka-Breganó20, there are several 
advantages in performing the universal prenatal screen-
ing in early pregnancy, namely: a) the possibility to rec-
ommend preventive measures to seronegative mothers; 
b) identification of pregnant women with asymptomatic 
acute infection and an appropriate treatment onset; c) 
increased care to the fetus and newborn; d) detection of 
maternal seroconversion by monitoring the serum of ini-
tially seronegative pregnant women; e) identification of 
pregnant women with chronic infection, who do not pose 
risks to the fetus. 
Austria and France were the first countries to establish 
programs for prenatal screening of toxoplasmosis in 1975 
with quarterly serological monitoring and in 1976, with 
monthly serological monitoring, respectively13,21, both 
aiming at establishing preventive measures for seronega-
tive women and ensure both diagnosis and early treat-
ment of infection acquired during pregnancy. In these 
programs, if the serological screening indicated acute in-
fection, maternal treatment starts with spiramycin in an 
attempt to prevent transmission to the fetus and, if fetal 
infection is confirmed by PCR of the amniotic uid, spira-
mycin is substituted by a triple regimen consisting of pyri-
methamine, sulfadiazine or sulfadoxine and folinic acid21. 
The French program was associated with a decline in 
both the incidence of congenital infection, as well as of 
severe disease detected at birth22 and the prevalence 
of toxoplasmosis in pregnant women in that country de-
creased from 84% in the 1960s to 54% in 1995 to 44% 
in 200323. The seropositivity among pregnant women in 
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Austria decreased from 50% at the end of the 1970s to 
35% in the 1990s24. 
Since 2007, pregnancy and congenital toxoplasmosis 
surveillance has been performed by the French Nation-
al Institute for Public Health Surveillance (InVS) of the 
National Reference Center for Toxoplasmosis, and aims 
to obtain information on cases of congenital toxoplas-
mosis diagnosed during pregnancy by amniocentesis or 
in newborns and children under one year whose mother 
seroconverted during pregnancy. Thus, one can estimate 
the overall prevalence of infection in France, follow the 
trends of prevalence and estimate the proportion of severe 
forms of infection (hydrocephalus, microcephaly, and ret-
inochoroiditis)23. 
Other countries such as Slovenia, Germany, Switzer-
land, Italy and Belgium also perform extensive screening 
during pregnancy; however, it is not performed in the en-
tire country14. 
The prenatal screening, although advocated by some 
experts as essential to reduce congenital toxoplasmosis16, 
has some limitations. Serological tests that detect IgM anti-
bodies, present in recent infections, are most oen used for 
diagnosis of acute toxoplasmosis; however, the most mod-
ern methods detect minimal amounts for more than a year 
aer the initial infection (residual IgM)25, limiting its use. 
A false-positive IgM antibody result (residual IgM) brings 
much anxiety to the mother and her family and reduces the 
positive expectations regarding the new child26. Thus, this 
antibody should not be used as the only marker of acute in-
fection, in order not to expose the mother and fetus to un-
necessary risk for fetal diagnosis and treatment procedures. 
There are also the medical risks of fetal diagnostic pro-
cedures, where the amniocentesis is required, and several 
reports have identified risk factors associated with fetal 
loss and other complications for both mother and the fe-
tus, and the side eects of treatment26,27. 
Another disadvantage occurs in countries where the 
prevalence is lower, as they will have a higher cost of ma-
ternal screening due to the higher number of seronegative 
pregnant women who would need to repeat the serology 
during pregnancy. Based on these considerations, some 
experts recommend, for countries where the prevalence 
and incidence are low, to perform serological screening 
only in women at high risk of becoming infected by eating 
raw meat or having contact with soil, associated with pri-
mary prevention measures28  or neonatal screening14. 
Some countries such as the United Kingdom, for in-
stance, have adopted only educational practices in pregnant 
women considered to belong to high risk groups, according 
to the anamnesis, in order to reduce the risk of infection17. 
Primary prevention based on pre-natal education also 
proved to be eective, showing to be a good strategy to re-
duce congenital toxoplasmosis, as it does not interfere with 
any other prevention strategies (secondary and tertiary)2. 
NEONATAL SCREENING PROGRAMS
The neonatal screening adopted in Poland15, Denmark14 
and some US cities29, countries with low prevalence of 
congenital toxoplasmosis, consists in the diagnosis of neo-
natal infection by detecting specific IgM to Toxoplasma in 
newborn screening test or “heel prick test”. It is known that 
about 90% of infected children are asymptomatic at birth 
and clinical symptoms appear later30,31.
In the US, Boyer et al.16 and Montoya and Rosso32 rec-
ommend that newborn screening be performed, as the in-
cidence of congenital toxoplasmosis is equal or higher than 
other genetic and metabolic disorders (phenylketonuria, 
congenital hypothyroidism, congenital adrenal hyperpla-
sia), for which neonatal screening is mandatory by law in 
many states. In Massachusetts and New Hampshire, USA, 
all babies go through screening for toxoplasmosis since 
1986, by the “New England Regional Newborn Screening 
Program.” During the period from 1986 to 1992, of 635,000 
newborns that underwent serological tests, 52 were infect-
ed with Toxoplasma gondii, which represented an infection 
rate of approximately one per 10,000 live births33. 
Several studies have demonstrated that the detection 
of anti-T.  gondii IgM antibodies using the paper filter 
technique, identified about 85% of infected children14,15,33. 
However, Gilbert et al.34 using various techniques for de-
tection of IgM antibodies (ISAG, ELISA, immunouores-
cence) and IgA antibodies (ISAGA, ELISA) reported that 
only 52 to 55% of newborns are IgM-reagents, varying 
according to the trimester in which the mother serocon-
verted. 
Neonatal screening, when adopted as a single measure, 
is only responsible for the treatment of the newborn, fail-
ing to treat the mother, but this strategy when complemen-
tary to the maternal screening, becomes a beneficial tool 
for both. 
PROGRAMS FOR CONTROL OF CONGENITAL TOXOPLASMOSIS 
IN BRAZIL
In Brazil, prenatal screening is suggested as a non-man-
datory public policy due to the high prevalence of mater-
nal toxoplasmosis (higher than 40%) being free of costs in 
some regions, with isolated experience and their own pro-
tocols, but without consistency in actions, such as Mato 
Grosso do Sul, Minas Gerais, São Paulo and Goiás, and 
the cities of Curitiba in Paraná and Porto Alegre in Rio 
Grande do Sul5,25,35-38.
In Mato Grosso do Sul and Goiás, the prenatal screen-
ing program is based on a single test performed at the first 
prenatal consultation and the serological monitoring of 
initially negative women is not carried out36,37. The pro-
gram in Belo Horizonte, state of Minas Gerais, includes 
a new serological test in the third trimester of gestation25, 
whereas in Porto Alegre and Curitiba serology is repeated 
every trimester5,35. 
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The “Curitiba Mother” program, one of the first imple-
mented in Brazil by the Municipal Health Secretariat of 
Curitiba, state of Paraná, warrants special attention to the 
pregnant woman, establishing at which hospital the moth-
er will give birth from their first prenatal consultation at 
the Basic Health Unit (UBS). Serology for IgG and IgM 
are performed at the first consultation and repeated in the 
second and third trimesters if the test result is nonreactive 
and if the patient is at high risk for acquiring the infection. 
If the pregnant woman is considered low risk, the serology 
is repeated between the 26th and 28th weeks of gestation. 
In cases of positive serology for IgG and IgM, the result is 
confirmed by the IgG avidity test35.
The inclusion of toxoplasmosis in the Neonatal Screen-
ing Program, which complements the maternal screen-
ing in Brazil, has been suggested by several specialists5,39. 
Vasconcellos-Santos et al.40 found 190 confirmed cases of 
infection in newborns of Minas Gerais, corresponding to a 
prevalence of 1 in 770 live births in this population. 
The ophthalmologic assessment was decisive in 28 
children (15.7%) who were suspected of congenital toxo-
plasmosis at the neonatal screening (positive or indetermi-
nate IgM) disclosing retinochoroidal lesions, suggestive of 
toxoplasmosis, allowing confirmation that they had been, 
in fact, congenitally infected. The authors also emphasize 
that neonatal screening provides other advantages such as 
lower cost and relative simplicity, and allows the study of 
large samples.  
Furthermore, many women still do not attend regu-
lar prenatal consultations and when the mother acquires 
the infection aer the serology was performed, a stage in 
which the fetal transmission rate is higher, these cases can 
be detected by neonatal screening20. 
HEALTH SURVEILLANCE PROGRAM FOR PREGNANCY-ACQUIRED 
AND CONGENITAL TOXOPLASMOSIS IN THE CITY OF LONDRINA
The Health Surveillance Program for Pregnancy-Acquired 
and Congenital Toxoplasmosis was implemented in the 
city of Londrina in 2006 and is based on the first sero-
logical screening in the prenatal consultation, oâering 
recommendations on the prevention measures and sero-
logical monitoring every trimester in initially seronegative 
pregnant women for toxoplasmosis and the monitoring 
of pregnant women and children with acute toxoplasmo-
sis, as well as case reporting. 
A group of experts from various areas (Health Surveil-
lance Secretariat of the Ministry of Health, Health Depart-
ment of the State of Paraná, Londrina State University) 
established protocols for the diagnosis, treatment and con-
ducts of mothers and children that were tested and validat-
ed in the public health system of this city. These protocols 
were included in the manual: “Pregnancy-acquired and 
Congenital Toxoplasmosis: Manual of Health Surveillance, 
Diagnosis, Treatment and Conducts” 41. 
The program is currently implemented in other cities 
of Paraná such as Rolândia, Cambé, Cascavel, Palotina and 
Jesuítas, and undergoing implementation in Ibiporã 
and Maringá. The implementation process is divided into 
four phases:
1. Adequacy of the program actions: based on the 
definition of the âow chart of activities, laborato-
ries that will perform the serological screening (for 
IgG and IgM) and confirmatory (IgG avidity test up 
to 16 weeks of gestation), of the reference ambula-
tories that care for pregnant women and children 
with toxoplasmosis; of the notification system and 
drug supply for each participating municipality.
2. Training workshops: Training workshops address-
ing aspects of the life cycle of the parasite, with em-
phasis on transmission and prevention, laboratory 
diagnosis and program actions to be implemented. 
The workshops should be directed at three target 
groups that care for pregnant women and children: 
physicians (gynecologists, pediatricians, infectolo-
gists, ophthalmologists, neonatologists), nurses 
that work at the epidemiological surveillance de-
partment of the municipality and the FHP (Fam-
ily Health Program) teams; biochemists in charge 
of the serological screening and confirmation, and 
community health and nursing assistants.
3. Start of activities in the basic health units (UBS): 
implementation of the program in all UBS, man-
aged by a coordinator appointed by the Health 
Department of the Municipality and with the tech-
nical support of the project participants. To give 
recommendations on the preventive measures, 
materials will be made available for the pregnant 
women (booklets, brochures, video animation and 
posters). 
4. Program monitoring and evaluation: monitoring 
of program activities carried out through visits and 
regular meetings in the municipalities participating 
in the program for the detection and resolution of 
problems and diâ culties. 
The program evaluation in Londrina showed a 63.9% 
reduction in the number of pregnant women and 42.6% 
in the number of children referred to reference services 
(HU/UEL) for the treatment of toxoplasmosis, resulting 
in the increase of beds/treatment for pregnant women 
and children with other diseases. As for drugs, there was 
a reduction of 62.3% in the use of folinic acid and 67.4% 
of sulfadiazine. Moreover, the definition of the protocols 
resulted in the standardization of care and safety for the 
decision-making by the physicians20.
Aâ er the implementation of the “Health Surveillance 
Program for Pregnancy-Acquired and Congenital Toxo-
plasmosis” in Londrina, a study was conducted with preg-
nant women seeking care in the public health system and 
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who started prenatal care in the first trimester of pregnancy 
and seropositivity of 49.2% of anti-T. gondii IgG antibodies 
was found in a sample of 492 pregnant women. Among 
the variables analyzed, an association was observed 
with the low per capita income, low educational level, the 
presence of a cat in the residence and the habit of eating 
raw vegetables. There was no association with the inges-
tion of raw or undercooked meat and contact with soil42. 
In another study carried out in Londrina, with all preg-
nant women treated at a UBS between January and July 
2007, totaling 634 pregnant women, the authors observed 
a 50.5% prevalence of anti-T. gondii IgG antibodies and a 
significant association with residing in rural areas, more 
than one pregnancy, low educational level (<â8âyears of 
schooling) and low per capita income. 
In Rolândia a 54.4% prevalence of anti-T.  gondii IgG 
antibodies was observed and association with residing in 
rural areas, more than one pregnancy, low educational 
level, low per capita income, age (<â20âyears) and a trend 
towards statistical association with the consumption of 
untreated water was found. 
The pregnant women in Cambé had a prevalence of 
46.4% of anti-T. gondii IgG antibodies and association only 
between low educational level and low per capita income. 
In Cascavel, the authors found a 53.0% prevalence of anti-
T. gondii IgG antibodies and a significant association with 
age, more than one pregnancy and low per capita income. 
In the city of Palotina, a prevalence of 61.3% of anti-
T. gondii antibodies was found and the association between 
low education level, more than one pregnancy, the presence 
of cats in the residence and the habit of eating the colonial 
salami, which is typical of this region, was observed. 
This model of health surveillance program for toxo-
plasmosis can be implemented in any Brazilian city, and 
based on it, one can obtain epidemiological data, which 
associated with the geographic, sociodemographic and 
cultural characteristics, contribute to define strategies for 
disease control. The Ministry of Health is using this pro-
gram as a model to implement toxoplasmosis surveillance 
at national level.  
FINAL CONSIDERATIONS 
As the maternal, fetal and neonatal diagnostic param-
eters are complex and diâ cult to interpret, and there is no 
technique standardization, interpretations are discordant 
and the lack of awareness of the limitations of the various 
techniques for detecting antibodies further complicates 
the diagnosis. There are several individualized protocols 
in diâerent departments and regions which adopt diâer-
ent diagnostic and therapeutic measures without evaluat-
ing the results. In addition, there is no standardized set of 
measures that aims to give preventive guidance to such ex-
tension in order to reach the healthcare system entrance. 
The establishment of an ideal and consensual conduct 
with technical support will result in the adoption of mea-
sures which will certainly result in cost decrease for the 
Public Health System and the reduction in congenital 
toxoplasmosis.  
Moreover, it is essential that each country or each re-
gion have its own epidemiological information to establish 
control programs, particularly for pregnant women, as the 
incidence and prevalence of toxoplasmosis vary from re-
gion to region within the country. This variation is related 
to dietary habits, contact with the soil, presence of cats, 
ruralization of domiciles and other less well-established 
factors. The access to epidemiological data allows the 
evaluation of the cost-eâectiveness of measures, including 
direct and indirect health costs, considering the prevented 
fetal and neonatal infections. 
Recently, the Ministry of Health has approved Decree# 
2472 of 31 August 2010, Annex III, which establishes the 
list of Compulsory Notification in Sentinel Units (LNCS), 
including notification of gestational acute and congenital 
toxoplasmosis, which will allow the evaluation of control 
programs and will provide data for the implementation of 
a nationwide program. 
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